Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice

被引:7
作者
Briggs, Kelsey [1 ]
Kirby, Cara [1 ]
Beavis, Ashley C. [1 ]
Zengel, James [1 ,3 ]
Patil, Preetish [1 ]
Sauder, Christian [2 ]
He, Biao [1 ]
机构
[1] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA
[2] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA
[3] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA
关键词
Jeryl Lynn; mumps vaccine; ANTIBODIES; OUTBREAK; NEUROVIRULENCE; PATHOGENESIS; PERSISTENCE; GENE;
D O I
10.1128/jvi.01983-21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
At present, most individuals have received two doses of the measles, mumps, and rubella (MMR) vaccine, which contains genotype A mumps vaccine. One hurdle in developing a new mumps vaccine against circulating genotype G virus is whether the new genotype G vaccine can generate immunity in humans that are immunized against genotype A virus. Mumps virus (MuV) causes a highly contagious human disease characterized by the enlargement of the parotid glands. In severe cases, mumps can lead to neurological complications such as aseptic meningitis and encephalitis. Vaccination with the attenuated Jeryl Lynn (JL) MuV vaccine has dramatically reduced the incidence of MuV infection. Recently, large outbreaks have occurred in vaccinated populations. The vaccine strain JL was generated from genotype A, while most current circulating strains belong to genotype G. In this study, we examined the immunogenicity and longevity of genotype G-based vaccines. We found that our recombinant genotype G-based vaccines provide robust neutralizing titers toward genotype G for up to 1 year in mice. In addition, we demonstrated that a third dose of a genotype G-based vaccine following two doses of JL immunization significantly increases neutralizing titers toward the genotype G strain. Our data suggest that after two doses of JL vaccination, which most people have received, a third dose of a genotype G-based vaccine can generate immunity against a genotype G strain. IMPORTANCE At present, most individuals have received two doses of the measles, mumps, and rubella (MMR) vaccine, which contains genotype A mumps vaccine. One hurdle in developing a new mumps vaccine against circulating genotype G virus is whether the new genotype G vaccine can generate immunity in humans that are immunized against genotype A virus. This work demonstrates that a novel genotype G-based vaccine can be effective in animals which received two doses of genotype A-based vaccine, suggesting that the lead genotype G vaccine may induce anti-G immunity in humans who have received two doses of the current vaccine, providing support for testing this vaccine in humans.
引用
收藏
页数:13
相关论文
共 42 条
[1]   Mumps Vaccines: Current Challenges and Future Prospects [J].
Almansour, Iman .
FRONTIERS IN MICROBIOLOGY, 2020, 11
[2]  
ANDRABI A, 2013, J HLTH ALL SCI-INDIA, V3, P52, DOI DOI 10.1055/S-0040-1703633
[3]  
BUYNAK EB, 1966, P SOC EXP BIOL MED, V123, P768, DOI 10.3181/00379727-123-31599
[4]  
*CDC, 2019, MUMPS CAS OUTBR, DOI DOI 10.1371/JOURNAL.PONE.0114197
[5]  
Cohen C, 2007, EMERG INFECT DIS, V13, P12
[6]   Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines? [J].
Connell, Anna R. ;
Connell, Jeff ;
Leahy, T. Ronan ;
Hassan, Jaythoon .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[7]   Comparative study of the immune response in mice immunized with four live attenuated strains of mumps virus by intranasal or intramuscular route [J].
Cusi, MG ;
Correale, P ;
Valassina, M ;
Sabatino, M ;
Valensin, PE ;
Donati, M ;
Glück, R .
ARCHIVES OF VIROLOGY, 2001, 146 (07) :1241-1248
[8]   Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein [J].
Cusi, MG ;
Fischer, S ;
Sedlmeier, R ;
Valassina, M ;
Valensin, PE ;
Donati, M ;
Neubert, WJ .
VIRUS RESEARCH, 2001, 74 (1-2) :133-137
[9]   PERSISTENCE OF ANTI-MUMPS VIRUS-ANTIBODIES AFTER A 2 DOSE MMR VACCINATION - A 9-YEAR FOLLOW-UP [J].
DAVIDKIN, I ;
VALLE, M ;
JULKUNEN, I .
VACCINE, 1995, 13 (16) :1617-1622
[10]  
DEWAR RS, 1950, LANCET, V258, P256